MA28985B1 - Analogues de loxapine et methodes d'utilisation - Google Patents

Analogues de loxapine et methodes d'utilisation

Info

Publication number
MA28985B1
MA28985B1 MA29765A MA29765A MA28985B1 MA 28985 B1 MA28985 B1 MA 28985B1 MA 29765 A MA29765 A MA 29765A MA 29765 A MA29765 A MA 29765A MA 28985 B1 MA28985 B1 MA 28985B1
Authority
MA
Morocco
Prior art keywords
methods
loxapine
analogues
relates
novel compounds
Prior art date
Application number
MA29765A
Other languages
English (en)
Inventor
Dale M Edgar
David G Hangauer
Kazumi Shiosaki
Michael Solomon
James F White
Original Assignee
Hypnion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hypnion Inc filed Critical Hypnion Inc
Publication of MA28985B1 publication Critical patent/MA28985B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D267/20—[b, f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

L'invention concerne de nouveaux composés et des méthodes d'utilisation de ceux-ci pour moduler le sommeil.
MA29765A 2004-09-21 2007-03-20 Analogues de loxapine et methodes d'utilisation MA28985B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61184904P 2004-09-21 2004-09-21
US67319805P 2005-04-19 2005-04-19

Publications (1)

Publication Number Publication Date
MA28985B1 true MA28985B1 (fr) 2007-11-01

Family

ID=36090680

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29765A MA28985B1 (fr) 2004-09-21 2007-03-20 Analogues de loxapine et methodes d'utilisation

Country Status (19)

Country Link
US (3) US7592333B2 (fr)
EP (1) EP1804804B1 (fr)
JP (1) JP5049129B2 (fr)
KR (1) KR101264444B1 (fr)
AT (1) ATE542536T1 (fr)
AU (1) AU2005286713B2 (fr)
BR (1) BRPI0515518A (fr)
CA (1) CA2580250C (fr)
CY (1) CY1112590T1 (fr)
DK (1) DK1804804T3 (fr)
EA (1) EA012610B1 (fr)
ES (1) ES2378452T3 (fr)
MA (1) MA28985B1 (fr)
MX (1) MX2007003032A (fr)
NO (1) NO20071604L (fr)
NZ (1) NZ553900A (fr)
PL (1) PL1804804T3 (fr)
PT (1) PT1804804E (fr)
WO (1) WO2006034414A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
WO2004064753A2 (fr) * 2003-01-23 2004-08-05 Acadia Pharmaceuticals Inc Utilisation de la n-desmethylclozapine pour le traitement de maladies neuropsychiatriques chez l'homme
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
BRPI0417749A (pt) 2003-12-22 2007-04-10 Acadia Pharm Inc composto, método de sintese de composto, bibliotecas combinatórias, composições farmacêuticas e métodos de tratamento de disfunções neuropsiquiátricas
BRPI0509524A (pt) * 2004-04-01 2007-09-18 Acadia Pharm Inc formas cristalinas de n-desmetilclozapina
US7563785B2 (en) * 2004-10-29 2009-07-21 Hypnion, Inc. Quetiapine analogs and methods of use thereof
WO2007053618A1 (fr) * 2005-10-31 2007-05-10 Acadia Pharmaceuticals Inc. Promédicaments d'agonistes muscariniques et méthodes de traitement de troubles neuropsychiatriques
US7762006B2 (en) * 2006-06-14 2010-07-27 Siestamed, Technologies Medical equipment drying device
CA2667826C (fr) * 2006-10-28 2013-10-08 Methylgene Inc. Inhibiteurs de l'histone desacetylase
DK2137180T3 (da) * 2007-03-15 2012-07-02 Andaman Therapeutics Inc Dibenzo[B,F][1,4]oxazapinforbindelser
US9220837B2 (en) 2007-03-19 2015-12-29 Insuline Medical Ltd. Method and device for drug delivery
US8622991B2 (en) 2007-03-19 2014-01-07 Insuline Medical Ltd. Method and device for drug delivery
EP2131900B1 (fr) 2007-03-19 2018-05-30 Insuline Medical Ltd. Dispositif d'administration de médicaments
WO2009081262A1 (fr) 2007-12-18 2009-07-02 Insuline Medical Ltd. Dispositif d'administration de médicament doté d'un capteur pour un fonctionnement en boucle fermée
RU2532893C2 (ru) 2008-11-07 2014-11-10 Инсьюлин Медикал Лтд. Устройство и способ доставки лекарственных средств
WO2014116684A1 (fr) * 2013-01-22 2014-07-31 Edward Roberts Modulateurs de récepteur de neuropeptide y non peptidique
CN107635549A (zh) 2015-03-26 2018-01-26 杰奎琳·M·艾弗森 抑制与宿醉相关的症状的方法和组合物
CN114929688B (zh) * 2019-10-21 2024-11-01 阿莱瑞恩公司 作为H1和5-HT2A-受体调节剂、用于治疗睡眠障碍的3-(4-(11H-二苯并[b,e][1,4]吖庚英-6-基)哌嗪-1-基)-和3-(4-(二苯并[b,f][1,4]氧杂吖庚英/硫杂吖庚英/二吖庚英-11-基)哌嗪-1-基)-丙酸衍生物
EP4788419A1 (fr) * 2023-10-07 2026-08-12 Inspire Medical Systems, Inc. Thérapie pulmonaire pour soins en cas d'apnée du sommeil

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL140242B (nl) * 1963-03-01 1973-11-15 Wander Ag Dr A Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
US3928356A (en) * 1967-10-06 1975-12-23 Fujisawa Pharmaceutical Co 10-{8 4-({107 -Hydroxy alkyl)-1-piperazimyl{9 -dibenzo (h,f) oxofins and thiepins and acetyl esters thereof
NL7110453A (fr) 1970-08-06 1972-02-08 Wander Ag Dr A
US4072756A (en) * 1973-05-17 1978-02-07 Sandoz Ltd. Tricyclo piperidino ketones and soporific compositions thereof
US4642903A (en) 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US4855326A (en) 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
JPH04211071A (ja) * 1990-03-05 1992-08-03 Hokuriku Seiyaku Co Ltd 多環式化合物
US5578322A (en) 1990-11-30 1996-11-26 Yamanouchi Pharmaceutical Co., Ltd. Quick release coated preparation
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5380473A (en) 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
ATE208615T1 (de) 1993-07-09 2001-11-15 Scherer Corp R P Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
US5895664A (en) 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5616344A (en) 1994-06-14 1997-04-01 Fuisz Technologies Ltd. Apparatus and process for strengthening low density compression dosage units and product therefrom
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
AR008371A1 (es) 1996-05-30 2000-01-19 Novartis Ag Una sal de adicion con acido de una 10-aminoalifatil-dibenz[b,f],oxepina, su empleo; procedimiento para su elaboracion, una 10-aminoalifatil-dibenz[b,f]oxepina, una preparacion farmaceutica que contiene dicha sal o dicha oxepina y un procedimiento para el tratamiento de enfermedades neurodegenerativ
ES2318869T3 (es) 1997-02-20 2009-05-01 Massachusetts Institute Of Technology Forma de dosificacion que presenta propiedades de dispersion rapida, metodos de uso y procedimiento para su fabricacion.
US6277406B1 (en) 1997-10-08 2001-08-21 Fuisz Technologies Ltd. Easily processed tablet compositions
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
US7189757B2 (en) 2001-10-16 2007-03-13 Hypnion, Inc. Treatment of sleep disorders using CNS target modulators
US20050049146A1 (en) 2001-11-05 2005-03-03 Chiarello John F. Use of substituted dibenzothiepine derivatives as insecticidal, acaricidal and nematicidal agents
WO2004056182A1 (fr) * 2002-12-20 2004-07-08 Basf Aktiengesellschaft Derives de dibenzo(hetero)azepine pesticides
US20060063754A1 (en) * 2004-09-21 2006-03-23 Edgar Dale M Methods of treating a sleep disorder

Also Published As

Publication number Publication date
US20060063928A1 (en) 2006-03-23
EA200700702A1 (ru) 2007-10-26
JP2008513510A (ja) 2008-05-01
NO20071604L (no) 2007-06-20
CY1112590T1 (el) 2016-02-10
EA012610B1 (ru) 2009-10-30
AU2005286713B2 (en) 2010-10-28
AU2005286713A1 (en) 2006-03-30
DK1804804T3 (da) 2012-02-20
EP1804804B1 (fr) 2012-01-25
ATE542536T1 (de) 2012-02-15
PT1804804E (pt) 2012-03-30
NZ553900A (en) 2010-10-29
JP5049129B2 (ja) 2012-10-17
PL1804804T3 (pl) 2012-08-31
CA2580250A1 (fr) 2006-03-30
WO2006034414A2 (fr) 2006-03-30
EP1804804A2 (fr) 2007-07-11
WO2006034414A3 (fr) 2006-09-08
US20090186872A1 (en) 2009-07-23
CA2580250C (fr) 2013-05-14
MX2007003032A (es) 2007-05-21
US8101596B2 (en) 2012-01-24
KR20070060126A (ko) 2007-06-12
KR101264444B1 (ko) 2013-05-20
US20060063755A1 (en) 2006-03-23
EP1804804A4 (fr) 2010-11-24
BRPI0515518A (pt) 2008-07-29
ES2378452T3 (es) 2012-04-12
US7592333B2 (en) 2009-09-22

Similar Documents

Publication Publication Date Title
NO20071604L (no) Loxapinanaloger og fremgangsmater for anvendelse derav.
WO2006049734A3 (fr) Analogues de quetiapine et leurs procedes d'utilisation
ATE416168T1 (de) Modulatoren des vanilloidrezeptors
DE60327306D1 (de) Modifizierter russ
BR0317715A (pt) Composições e processos de uso de collajolie
EP1810979A4 (fr) ANTICORPS IgGG4 HUMAINS STABILISES
SE0301653D0 (sv) Novel compounds
AU2003254177A8 (en) Substituted benzanilides as modulators of the ccr5 receptor
DK1549638T3 (da) Indol-3-carboxamider som glucokinase (GK) aktivatorer
AU2003256923A8 (en) Substituted benzanilides as modulators of the ccr5 receptor
EP1638977A4 (fr) Salinosporamides et leurs methodes d'utilisation
DE60126838D1 (de) Amidoacetonitrile zur Bekämpfung von Endoparasiten
DE60335716D1 (de) Beschleuniger-zusammensetzung
IL181445A0 (en) Use of (halobenzyloxy)benzylamino-propanamides for the manufacture of medicaments active as sodium and/or calcium selective modulators
DE60324641D1 (de) Schäumbare Emulsion des Öl-in-Waser-Typs
EP1874731A4 (fr) Analogues de quinobenzoxazines et procedes d'utilisation de ceux-ci
UY28344A1 (es) Nuevos compuestos
ATE448234T1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung
ATE365455T1 (de) Aminoacetonitril-verbindungen zur bekämpfung von endoparasiten
DE50309381D1 (de) Neue pyrimidin-4,6-dicarbons urediamide zur selektiven inhibierung von kollagenasen
MX2007002277A (es) Metodos para formar retinoides y usos de los mismos.
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
EP1809646A4 (fr) Riboswitches de glycine, méthodes d'utilisation et compositions s'utilisant avec les riboswitches
MX2007003398A (es) Sulfonamidas y sus usos.
IL178149A0 (en) Novel phenantridine analogues and their uses as inhibitors of hyperproliferation of t cells and/or keratinocytes